Applied DNA Announces Continued Momentum in COVID-19 Testing Demand


– FQ1’22 Testing Levels Up Over 90% Compared to FQ4’21, Reports Further Strengthening in FQ2’22 to Date – – Increase In Testing Levels Reflects Diversity in Demand and the On-boarding of New safeCircle™ Clients; Secures Subcontractor Award for Community-based Pop-Up Testing Service – STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN #COVID19Testing—Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has seen COVID-19 testing levels increase greater than 90% (unaudited) for the quarter ended December 31, 2021, compared to the fiscal quarter ended September 30, 2021. ADCL has also seen a further strengthening of demand since the quarter ended December 31, 2021, to date. ADCL attributes the increase in demand to current safeCircle™ clients seeking to safely reopen or increase activities at municipalities, campuses, and businesses and the on-boarding of new clients. ADCL’s safeCircle program is a fully integrated testing platform for enterprise and educational institutions that provides a full range of COVID-19 diagnostic testing and associated services, including sample collection, test site infrastructure design and management, results tracking, and vaccination status management. safeCircle’s sales prospects have also increased in number as enterprises seek to put into place managed COVID-19 testing practices to mitigate impacts and other risks to business continuity and to prepare themselves for further development of the COVID-19 pandemic and its possible scenarios. ADCL also announced that it secured a testing subcontract to service a municipal COVID-19 testing award. Under the testing subcontract, ADCL is testing COVID-19 samples provided by multiple community-based pop-up collection sites. Dr. James A. Hayward, president and CEO of Applied DNA, stated, “Our approach to COVID-19 testing remains strategic whereby we are focused on market segments in which we expect testing to…

Excerpt only …
Source : Applied DNA Announces Continued Momentum in COVID-19 Testing Demand

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.